Episode 14950:10:45
Organic Produce, Exercise vs Income, Cat Parasite, Thorne, Loss of Taste, and more... : 1495
The Human Upgrade: Biohacking for Longevity & Performance
Show notes
GLP-1 Side Effects, Gut Microbiome & Brain Health, Toxoplasmosis Risks, and the Dirty Dozen Explained
Plasma Acetate Emerges As Key Gut-Brain Messenger In Older Adults
A study published in Nature Communications examined how gut bacteria relate to plasma acetic acid, a short-chain fatty acid produced when gut microbes ferment fiber, and found that higher acetate levels tracked with lower triglycerides, higher HDL cholesterol, lower body fat, larger thalamic brain volume, and stronger performance on judgment-related cognitive tasks. Mediation analysis showed acetate acts as a direct link between specific gut bacteria, including Oscillibacter and Coprococcus, and these health outcomes. Host Dave Asprey breaks down why this elevates fiber fermentation, not fermented beverages, as the real lever for gut-brain health, and separates the evidence-backed mechanism from the kombucha-as-shortcut assumption.
Source:
https://www.nature.com/articles/s43856-026-01566-x
~~
GLP-1 Drugs Linked To Sharp Rise In Smell And Taste Disturbances
A JAMA Otolaryngology cohort study tracking over 438,000 GLP-1 users against matched controls found a 48% higher risk of new smell or taste disturbances over two years, with smell disturbances up 81% and taste disturbances up 52%. Diagnoses included anosmia, parosmia, and parageusia, with researchers pointing to GLP-1 receptor activity in the olfactory bulb and other chemosensory pathways as a possible mechanism. Host Dave Asprey unpacks why this signal got buried under muscle loss and gut motility headlines, and what it means for anyone currently on or considering GLP-1 therapy.
Sources:
https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2850571
https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2026.1498
~~
Scientists Push For Toxoplasmosis To Be Recognized As A Neglected Tropical Disease
A viewpoint paper in PLOS Neglected Tropical Diseases argues that toxoplasmosis, a parasitic infection carried by roughly one in three people globally, deserves WHO neglected tropical disease status given its outsized impact on vision and maternal-child health. Ocular toxoplasmosis is the most common intra-ocular infection worldwide, and an estimated 190,000 babies are born with congenital toxoplasmosis each year, concentrated in low-resource regions. Despite the scale, there is still no vaccine and no standard global treatment protocol. Host Dave Asprey explains why common, quiet health threats get chronically underfunded compared to dramatic outbreaks, and what pregnant listeners specifically should know about exposure risk.
Source:
~~
Yale-Oxford Data Shows Exercise May Boost Mental Health More Than A Raise
An analysis of CDC survey data from over 1.2 million U.S. adults found that people who exercise regularly report 1.5 to 2 fewer poor mental health days per month than non-exercisers, a benefit comparable to earning about $25,000 more per year. The data also revealed an inverted-U relationship, with optimal benefits at three to five sessions a week and diminishing or reversed returns at extreme volumes. Host Dave Asprey breaks down why moderate, consistent movement outperforms income as a mental health lever, and why overtraining carries its own psychological cost.
Sources:
~~
Unilever Reportedly Exploring $4 Billion Bid For Supplement Brand Thorne
Unilever is said to be evaluating a bid for Thorne, the clinical-grade supplement brand currently owned by private equity firm L Catterton, in a deal that could value the company at up to $4 billion, with Haleon also reportedly circling. The move reflects a broader trend of major consumer-health conglomerates acquiring practitioner-trusted, lab-forward wellness brands. Host Dave Asprey weighs in on what happens to product quality and innovation when founder-led, science-first supplement companies get absorbed into shareholder-first parent corporations.
Source:
~~
New Research Maps How Your Microbiome Processes Plant Compounds, And What It Means For Your Produce Aisle Choices
Researchers mapped 775 phytonutrients from over 1,100 edible plants against nearly 2,000 gut bacterial enzymes across thousands of human microbiomes, linking that enzyme activity to outcomes in IBD, colorectal cancer, and fatty liver disease. Individuals varied widely in how many of these compounds their gut could actually process, and in mouse studies, strawberries reduced colitis activity only in mice with an intact microbiome. Host Dave Asprey explains why the plant itself isn't the active ingredient, your bacteria are, and connects the findings to this year's Environmental Working Group Dirty Dozen and Clean Fifteen lists to help listeners decide where organic actually matters.
Sources:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12768975/
https://www.eurekalert.org/news-releases/1108351
https://www.nature.com/articles/s41564-025-02197-z
~~
This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insights into the gut-brain axis, an underreported GLP-1 side effect, a global parasite hiding in plain sight, the real ROI of exercise on mental health, consolidation in the supplement industry, and how your microbiome determines what your produce actually does for you. Host Dave Asprey connects clinical research, large cohort studies, mechanistic biology, and industry news into practical frameworks for improving gut health, brain performance, and long-term resilience.
New episodes every Tuesday, Thursday, Friday, and Sunday.
Keywords: plasma acetate gut brain axis, short chain fatty acids, gut microbiome cognition, GLP-1 smell taste disturbances, anosmia parosmia GLP-1, semaglutide side effects, toxoplasmosis neglected tropical disease, Toxoplasma gondii health risks, congenital toxoplasmosis, exercise mental health study, exercise versus income happiness, overtraining mental health, Unilever Thorne acquisition, supplement industry consolidation, phytonutrient gut bacteria enzymes, polyphenol metabolism microbiome, Dirty Dozen Clean Fifteen 2026, pesticide residue produce, biohacking news 2026, Dave Asprey, The Human Upgrade
Thank you to our sponsors!
- PredictiveMind™ | Get your Brain Pattern Mapping report at predictivemind.io/dave and use code DAVE for 10% off.
- Viome | Check it out at viome.com and use code 10DAVE for 10% off. It’s time to stop guessing and start knowing your body.
- iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE
Resources:
• Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/
• Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/
• Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today.
• Danger Coffee: https://dangercoffee.com/discount/dave15
• My Daily Supplements: SuppGrade Labs (15% Off)
• Favorite Blue Light Blocking Glasses: TrueDark (15% Off)
• Dave Asprey’s BEYOND Conference: https://beyondconference.com
• Dave Asprey’s New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated
• Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/
• Upgrade Labs: https://upgradelabs.com
Timestamps:
00:00 – Story #1: Acetate & Gut-Brain Health
01:57 – Story #2: GLP-1s & Smell/Taste Loss
03:22 – Story #3: Toxoplasmosis Risks
04:33 – Story #4: Exercise vs Income
05:53 – Story #5: Phytonutrients & Gut Enzymes
07:45 – Dirty Dozen & Clean Fifteen
08:46 – Story #6: Thorne Acquisition
09:49 – Takeaway
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.